# ROCK IMMUNE, INC.: Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | ROCK IMMUNE, INC. |
| Location | DENVER, CO |
| Project | Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia |
| Project number | 1R41CA309908-01 |
| Mechanism | R41 |
| Institute | National Cancer Institute |
| Award | $400,000 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-18 to 2027-08-31 |
| UEI | M35ZNF9XP8Q7 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11310680). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.